Sunovion Pharmaceuticals has published results in The American Journal of Psychiatry (AJP) of two trials supporting the FDA approval of Latuda (lurasidone HCl) for the treatment of adult patients with major depressive episodes associated with bipolar depression, both as monotherapy and as adjunctive therapy with lithium or valproate The two positive double-blind, randomized, placebo-controlled, six-week clinical trials showed that Latuda significantly reduced depressive symptoms in patients wit...